

Date: 14th July, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir / Madam,

**Sub: Submission of Unaudited Financial Results for the Quarter ended on
30th June, 2022 along with Limited Review Report
Ref: Security Id: EARUM / Code: 542724**

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Unaudited Financial Results for the Quarter ended on 30th June, 2022 along with Limited Review Report.

Please take note of the same and oblige.

For, **Earum Pharmaceuticals Limited**

Bhumishth Patel
Managing Director
02516641

EARUM PHARMACEUTICALS LTD. CIN:L24230GJ2012PLC071299

G-1, Ground Floor ,V R Complex ,Nr Sanathal Cross Road ,S P Ring Road ,Sanathal ,Ahmedabad-382210

PROFIT & LOSS ACCOUNT FOR THE QUARTER ENDED ON 30th JUNE 2022

Particulars	Quarter Ended			Year Ended
	30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	For the Period Ended 31st March 2022
	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)
I. Revenue from Operations	427.87	473.84	298.74	2,103.56
II Other Income	86.57	541.99	8.27	770.30
Total Revenue (I + II)	514.44	1,015.83	307.01	2,873.86
III. Expenses:				
Purchases of material	415.66	1009.42	304.44	2,182.54
Changes in Inventories	57.41	(13.47)	328.04	321.47
Employee Benefits Expenses	0.18	1.95	1.49	4.10
Finance Costs	0.00	0	7.26	8.22
Depreciation and Amortization expense	2.38	0.15	3.15	11.82
Other Expenses	2.51	3.62	3.93	37.54
Total Expenses	478.14	1,001.67	648.31	2,565.69
IV. Profit before exceptional and extraordinary items and tax (III-IV)	36.30	14.16	-341.30	308.17
V. Exceptional Items				
Prior Period Expenses				
VI. Profit Before Extraordinary Items and Tax (V - VI)	36.30	14.16	(341.30)	308.17
VIII. Extraordinary Items				
IX. Profit before tax (VII- VIII)	36.30	14.16	(341.30)	308.17
X Tax expense:				
(1) Current tax	0.00	86	32.77	85.76
(2) Deferred tax				
XI Profit (Loss) for the period from continuing operations (VII- VIII)	36.30	(71.60)	(374.07)	222.41
XII Other Comprehensive Income / (Loss)				
i) Items that will not be reclassified to profit and loss	-	-	-	-
ii) Items will be reclassified to profit and loss	-	-	-	-
XV Total Comprehensive Income/(Loss)	36.30	(71.60)	(374.07)	222.41
XVI BALANCE BROUGHT FROM PREVIOUS YEAR				
XVII BALANCE CARRIED TO BALANCE SHEET	36.30	(71.60)	(374.07)	222.41
XVIII Details of equity Share Capital				
Paid Up Equity Share Capital	1233.58	1233.58	616.79	1233.58
Other Equity	0.00	0.00	0.00	438.94
Face Value of equity share Capital	2.00	2.00	10.00	2.00
XIX Earnings per equity share:				
(1) Basic	0.29	-0.12	-5.53	0.36
(2) Diluted	0.29	-0.12	-5.53	0.36

Notes:

- These financial results were reviewed by the audit committee and thereafter have been approved by the board of directors at its meeting held on Thursday July 14, 2022. The Statutory Auditors have carried out Limited review of the financial results for the quarter ended June 30, 2022.
- These audited financial results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") prescribed under section 133 of the Companies Act, 2013
- IND AS 108 Relating to Segment wise reporting is not applicable as the Company operates in only One Primary segment i.e Pharmaceutical Trading
- Previous year/quarter figures have been regrouped/rearranged wherever necessary.

For, Earum Pharmaceuticals Limited

Bhumishth Patel
Managing Director
DIN : 02516641
Ahmedabad
Date : 14/07/2022



J. M. PATEL & BROS.

Chartered Accountants

E-mail : jmpatelca@yahoo.co.in

204, Harsh Avenue,
Navjivan Press Road,
Nr. Old High Court Crossing,
AHMEDABAD-380 014.
Phone : (079) 27541460

Ref. No. :

Date :

LIMITED REVIEW REPORT OF EARUM PHARMACEUTICALS LIMITED

Review Report to


To,
**The Board of Directors,
Earum Pharmaceuticals Limited**


We have reviewed the accompanying statement of unaudited financial results of **Earum Pharmaceuticals Limited** for the Quarter ended **30th June, 2022**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion except notes on last para.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement and subject to State Bank of India CC Accounts Rs. 8.74 Crores outstanding are inoperative and No provision for interest Rs. 21.85 Lakhs(Approx.) on S.B.I. loan is not made into accounts. Also Expenses (Other than Depreciation) are reduced from Rs. 12.68 Lakhs for quarter Ended 30/06/2021 to Rs. 2.69 Lakhs for quarter Ended 30/06/2022. Even sales increase in current quarter.

For J M PATEL & BROS.,
CHARTERED ACCOUNTANTS
FRN: 107707W


CA JASHWANT M. PATEL
Partner
M. No. 030161
UDIN: 22030161AMWAWS1306



Place: Ahmedabad
Date: 14/07/2022